TREATMENT OF THE METABOLIC-ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH  METABOLIC SYNDROME

dc.contributor.author	SOBIROVA G.N., SAIDRASULOVA G.B., KARIMOV M.M.
dc.date.accessioned	2024-12-12T20:50:12Z
dc.date.available	2024-12-12T20:50:12Z
dc.date.issued	2024
dc.identifier.uri	http://repo.tma.uz/xmlui/handle/1/303
dc.description.abstract	The study was conducted at Tashkent medical academy between 2022-2024. The study participated 165 patients with metabolic syndrome with signs of MAFLD also. Patients included to research with age between 45 and 75 years old. All participants were subject to demographic data, clinical, functional and biochemical markers	en_US
dc.language.iso	other	en_US
dc.publisher	"Ichki kasalliklarining dolzarb muammolari” mavzusida Xalqaro terapevtlar forumi	en_US
dc.subject	Aim. To evaluate the effect of supplementation with ademetionine for 3 months on lipidic and biochemical parameters in patients with metabolic syndrome and at risk of MAFLD	en_US
dc.title	TREATMENT OF THE METABOLIC-ASSOCIATED FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME	en_US
dc.type	Thesis	en_US